{
    "nctId": "NCT02307227",
    "briefTitle": "Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors",
    "officialTitle": "Antitumor Immune Responses in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: a Phase II Study With Trastuzumab and Concomitant Weekly Paclitaxel in Patients With HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 46,
    "primaryOutcomeMeasure": "Pathological complete response (pCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically proven breast carcinoma evaluated for HER 2 status and immune status\n* Locally advanced carcinoma (UICC stage II-III)\n* Age \\< 70 years\n* measurable lesions\n* ECOG Performance Status 0-2\n* Life expectancy \\> 3 months\n* Adequate bone marrow and hepatic functions\n* Creatinine Clearance \\> 40 ml/min\n* Written informed consent\n* Patients must be accessible for treatment and follow up.\n\nExclusion Criteria:\n\n* Prior chemotherapy or hormonal treatments\n* Brain metastases.\n* Past or current history of neoplasm other than curatively treated.\n* Concurrent treatment with other experimental drugs.\n* Left Ventricular Ejection Fraction (LVEF) \\<50 %\n* History of significant neurological or psychiatric disorders.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}